Re: Homocysteine lowering and cardiovascular events
- From: "GaryG" <sorrynoemail@xxxxxxxxxxx>
- Date: Mon, 19 Jun 2006 07:12:34 -0700
"David R. Throop" <throop@xxxxxxxxxxxxx> wrote in message
news:e767i1$me5$1@xxxxxxxxxxxxxxxxxxxxxxxxxx
Somebody was asking for studies backing the claim that loweringhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16531614
homocysteine by using vitamin B doesn't actually protect against
heart attack.
This study came out in April in NEJM. The abstract is pubmed 16531614
Also check out
http://en.wikipedia.org/wiki/Folic_acid#Folic_acid_and_heart_disease
which has links to several other studies showing no benefit.
DRT
===========================================y
Homocysteine lowering and cardiovascular events after acute myocardial
infarction.
Interesting...but I'd prefer to see a study among people who had not
previously had an MI.
GG
Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T,
Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial
Investigators.
Institute of Community Medicine, University of Tromso, Tromso,
Norway. kaare.bonaa@xxxxxxxxx
BACKGROUND: Homocysteine is a risk factor for cardiovascular
disease. We evaluated the efficacy of homocysteine-lowering treatment
with B vitamins for secondary prevention in patients who had had an
acute myocardial infarction. METHODS: The trial included 3749 men and
women who had had an acute myocardial infarction within seven days
before randomization. Patients were randomly assigned, in a two-by-two
factorial design, to receive one of the following four daily
treatments: 0.8 mg of folic acid, 0.4 mg of vitamin B12, and 40 mg of
vitamin B6; 0.8 mg of folic acid and 0.4 mg of vitamin B12; 40 mg of
vitamin B6; or placebo. The primary end point during a median
follow-up of 40 months was a composite of recurrent myocardial
infarction, stroke, and sudden death attributed to coronary artery
disease. RESULTS: The mean total homocysteine level was lowered by 27
percent among patients given folic acid plus vitamin B12, but such
treatment had no significant effect on the primary end point (risk
ratio, 1.08; 95 percent confidence interval, 0.93 to 1.25;
P=0.31). Also, treatment with vitamin B6 was not associated with any
significant benefit with regard to the primary end point (relative
risk of the primary end point, 1.14; 95 percent confidence interval,
0.98 to 1.32; P=0.09). In the group given folic acid, vitamin B12, and
vitamin B6, there was a trend toward an increased risk (relative risk,
1.22; 95 percent confidence interval, 1.00 to 1.50;
P=0.05). CONCLUSIONS: Treatment with B vitamins did not lower the risk
of recurrent cardiovascular disease after acute myocardial
infarction. A harmful effect from combined B vitamin treatment was
suggested. Such treatment should therefore not be
recommended. (ClinicalTrials.gov number, NCT00266487.). Copyright 2006
Massachusetts Medical Society.
.
- Follow-Ups:
- Re: Homocysteine lowering and cardiovascular events
- From: David Rind
- Re: Homocysteine lowering and cardiovascular events
- From: Jason Johnson
- Re: Homocysteine lowering and cardiovascular events
- References:
- Homocysteine lowering and cardiovascular events
- From: David R. Throop
- Homocysteine lowering and cardiovascular events
- Prev by Date: Chung FLIPS OUT!
- Next by Date: Vegetables may help arteries stay clear
- Previous by thread: Homocysteine lowering and cardiovascular events
- Next by thread: Re: Homocysteine lowering and cardiovascular events
- Index(es):
Relevant Pages
|
